尿道注入利多卡因及地塞米松在前列腺增生导尿困难应用的对比研究  

Comparative study of urethral injection of lidocaine and dexamethasone in patients with prostatic hyperplasia

作　　者：郑海涛 冯光日 孙世宏 邱晓蓉 赵岩岩 ZHENG Hai-tao;FENG Guang-ri;SUN Shi-hong(SuHuaZan hospital of Shiqi,Zhongshan 528400,China)

机构地区：[1]中山市石岐苏华赞医院外科,广东中山528400

出　　处：《中国处方药》2019年第2期4-6,共3页Journal of China Prescription Drug

基　　金：中山市医学科研基金项目(2017A020233)

摘　　要：目的探究尿道注入利多卡因及地塞米松在前列腺增生导尿困难患者中的作用效果。方法将入选的90例患者随机分为三组,试验A组(A组)、试验B组(B组)及对照组(C组),每组30例。A组尿道注入2%利多卡因5 m L+石蜡油5 m L,B组尿道注入0.25%地塞米松4 m L+石蜡油5 m L,C组尿道口注入石蜡油10 m L。比较三组的平均导尿时间,一次性置管成功率,不良反应(尿道刺激及出血等)发生率,及置管过程中患者疼痛程度等指标。结果 A组与B组的一次性置管成功率无明显差异,C组的一次性置管成功率显著低于A组与B组(P <0.05);A组与B组的平均置管时间无统计学差异(P> 0.05),C组平均置管时间最长且差异具有统计学意义(P <0.05);A组与B组不良反应发生率无明显差异(P> 0.05),C组不良反应发生率明显高于A组与B组(P <0.05);A组患者疼痛反应最轻,B组次之,C组疼痛反应最重,差异具有统计学意义(P<0.05)。结论在客观指标方面A组与B组无显著差异,但是在主观指标患者疼痛程度方面,A组疼痛反应低于B组,利多卡因在前列腺增生导尿困难患者中效果更好。Objective To investigate the effect of urethral injection of lidocaine and dexamethasone in patients with prostatic hyperplasia and dysuria.Methods A total of 90 patients were randomly divided into three groups(test group A,test group B and control group C,30 people in each group).Before insertion of catheter,urethra injection of 2%lidocaine 5 mL+paraffin oil 5mL were for test group A,0.25%dexamethasone 4 mL+paraffin oil 5 mL for test group B,and 10 mL of paraffin oil for the control group C.The average catheterization time,the rate of one-time catheterization,the incidence of adverse reactions(urinary tract irritation and hemorrhage,etc.),and the degree of pain in the catheterization process were compared between the three groups.Results There was no significant difference in the success rate of one-time tube placement between group A and group B.The success rate of one-time tube placement in group C was significantly lower than that in group A and group B.There was no significant difference in the average tube placement time between group A and group B.The average tube placement time in group C was the longest and the difference was statistically significant.There was no significant difference in the incidence of adverse reactions between group A and group B.The incidence of adverse reactions in group C was significantly higher than that in group A and group B.The pain response in group A was the lightest.In group B,the pain response was the most severe in group C,and the difference was statistically significant.Conclusion There was no significant difference between group A and group B in terms of objective indicators,but the pain response of group A was lower than that of group B.Lidocaine was better in patients with prostatic hyperplasia and dysuria.It is worthy of clinical promotion.

关 键 词：前列腺增生 导尿 利多卡因 地塞米松 

分 类 号：R697.3[医药卫生—泌尿科学]